カンツズマブメルタンシン、カンツズマブ・メルタンシン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2018/06/06 15:49:48」(JST)
[Wiki en表示]
Cantuzumab mertansine
|
| Monoclonal antibody |
| Type |
Whole antibody |
| Source |
Humanized (from mouse) |
| Target |
MUC1 |
| Clinical data |
| ATC code |
|
| Identifiers |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
| Y (what is this?) (verify) |
Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2] It was developed by ImmunoGen.
Contents
- 1 Mechanism
- 2 Clinical trials
- 3 See also
- 4 References
Mechanism
After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.[3]
Clinical trials
Three phase I clinical studies had reported results by 2003.[4] By 2005, clinical development had been suspended.[5]
See also
References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association.[dead link]
- ^ Rodon, J; Garrison, M; Hammond, LA; de Bono, J; Smith, L; Forero, L; Hao, D; Takimoto, C; Lambert, JM; Pandite, L; Howard, M; Xie, H; Tolcher, AW (2008). "Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study". Cancer Chemother Pharmacol. 62: 911–9. doi:10.1007/s00280-007-0672-8. PMID 18301896.
- ^ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
- ^ http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=354351&highlight=
- ^ http://adisinsight.springer.com/drugs/800007546
|
Monoclonal antibodies for tumors
|
Tumor
("-t(u[m])-") |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 転移性乳癌の全身治療：分子標的治療 systemic treatment for metastatic breast cancer molecular targeted therapy
English Journal
- Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
- Rodon J1, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW.
- Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2008 Oct;62(5):911-9. doi: 10.1007/s00280-007-0672-8. Epub 2008 Feb 27.
- PMID 18301896
- Gateways to clinical trials.
- Bayés M, Rabasseda X, Prous JR.
- Methods and findings in experimental and clinical pharmacology.Methods Find Exp Clin Pharmacol.2005 Apr;27(3):193-219.
- Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.c
- PMID 15834452
- Technology evaluation: cantuzumab mertansine, ImmunoGen.
- Smith SV1.
- Current opinion in molecular therapeutics.Curr Opin Mol Ther.2004 Dec;6(6):666-74.
- PMID 15663331
★リンクテーブル★
[★]
- 英
- cantuzumab mertansine
- 関
- カンツズマブ・メルタンシン
[★]
- 英
- cantuzumab mertansine
- 関
- カンツズマブメルタンシン